Skip to content Skip to footer
Subscribe Now
Top 20 Biopharma Deal Terminations of 2025
TOP 20

Top 20 Biopharma Deal Terminations of 2025 

Shots:  Biopharma dealmaking in 2025 continued to face significant headwinds, with collaborations frequently collapsing due to strategic reprioritization, fierce competitive pressures, unfavorable clinical readouts, and failure to meet key closing conditions highlighting the inherent uncertainty and capital risk embedded in innovation-driven partnerships   The year underscored a clear dominance of R&D-focused collaborations and licensing agreements,…
9 hours ago

Read more

VIEWPOINTS_Curtis Rambaran_2023
VIEWPOINTS

Curtis Rambaran’s Insights from Zerlasiran P-II Study for Patients with Elevated Lipoprotein (a) at High-Risk ASCVD Events

Shots: Curtis gave a brief introduction about Zerlasiran. He also talked about the study design and the results from the P-II trial (ALPACAR-360) under which Zerlasiran is being evaluated He also highlighted how Zerlasiran can differ from other therapies that are in development to treat elevated lipoprotein (a) at high risk of atherosclerotic cardiovascular disease (ASCVD)…
August 28, 2023

Read more

RNAi Therapeutic Top 20 2022
TOP 20

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

Shots: RNAi Therapeutic leverages the biological response of degrading (mRNA) before it gets translated into a protein. By using short double-stranded RNA in silencing a targeted disease-causing mutation, researchers are working steadfastly in multiple indications to expand RNAi therapeutic RNAi therapy comes to the rescue when targeting a specific protein gets difficult using a conventional…
April 25, 2023

Read more